Teserpaturev/G47Δ (Delytact^®) is a third-generation (triple-mutated) recombinant oncolytic herpes simplex virus type 1 being developed by Daiichi Sankyo Co., Ltd. for the treatment of certain solid cancers. Teserpaturev/G47Δ has been approved for the treatment of malignant glioma in Japan and is currently in clinical development for the treatment of prostate cancer (phase II), malignant pleural mesothelioma (phase I) and recurrent olfactory neuroblastoma (phase I). This article summarizes the milestones in the development of teserpaturev/G47Δ leading to this first approval for the treatment of malignant glioma.

中文翻译：

---

Teserpaturev/G47Δ：首次批准

Teserpaturev/G47Δ (Delytact ^® ) 是第一三共株式会社开发的第三代（三重突变）重组溶瘤单纯疱疹病毒 1 型，用于治疗某些实体癌。Teserpaturev/G47Δ已在日本获批用于治疗恶性神经胶质瘤，目前正处于治疗前列腺癌（II期）、恶性胸膜间皮瘤（I期）和复发性嗅神经母细胞瘤（I期）的临床开发阶段。本文总结了 teserpaturev/G47Δ 开发的里程碑，导致首次批准用于治疗恶性神经胶质瘤。